EUVIMEDEUVIMED entdecken
Crossref

Evaluating the benefits and risks of puberty blockers and gender‐affirming hormones for transgender adolescents

Daniel Wright iD, Ken C Pang, Simona Giordano, Lynn Gillam

Journal of Paediatrics and Child Health · 2025-01 · 61 (1) · 7-11

DOI: 10.1111/jpc.16734 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Paediatrics and Child Health, online erschienen am 06.12.2024. Verfasst von Daniel Wright und 3 weiteren Autor:innen. Beteiligte Einrichtung: Children's Bioethics Centre, Royal Children's Hospital, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Transgender Persons. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: The Royal Children's Hospital Foundation, The Hugh D.T. Williamson Foundation, NHMRC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The use of puberty blockers and gender‐affirming hormones by transgender adolescents is the subject of an ongoing public debate. In this paper, we address one central ethical aspect of the debate – the question of what sort of benefits these treatments provide and how to evaluate the significance of these benefits in relation to risks. We argue that the intended benefit of these treatments is best understood as appearance congruence, namely, to create or maintain alignment of physical appearance with one's gender identity. The common focus on the mental health benefits associated with these treatments may obscure a range of experiential benefits sought by young people, such as positive gender experiences and being treated by others as one's identified gender. We also address concern about the risk that young people may revert to their assigned gender (de‐transition) and experience regret. We distinguish between de‐transition and regret, highlighting that regret appears to occur in a minority of instances of de‐transition or discontinuation of hormone treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transgender PersonsHumansAdolescentMaleFemaleRisk AssessmentPubertyGender IdentityPuberty Inhibitors

Substanzen

Puberty Inhibitors

Autor:innen und Institutionen

  • Children's Bioethics Centre, Royal Children's Hospital, Melbourne, Victoria, Australia.
  • Centre for Social Ethics and Policy (CSEP), Law School, School of Social Sciences, The University of Manchester, Manchester, UK.
  • Clinical Sciences, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
  • Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia.
  • Department of Adolescent Medicine, Royal Children's Hospital, Melbourne, Victoria, Australia.

ORCID-Profile: Daniel Wright

Förderung

  • The Royal Children's Hospital Foundation
  • The Hugh D.T. Williamson Foundation
  • NHMRC
  • Royal Children's Hospital Foundation
  • National Health and Medical Research Council

Zitieren

APA

Wright, D., Pang, K. C., Giordano, S., & Gillam, L. (2025). Evaluating the benefits and risks of puberty blockers and gender‐affirming hormones for transgender adolescents. Journal of Paediatrics and Child Health, 61(1), 7-11. https://doi.org/10.1111/jpc.16734

Vancouver

Wright D, Pang KC, Giordano S, Gillam L. Evaluating the benefits and risks of puberty blockers and gender‐affirming hormones for transgender adolescents. Journal of Paediatrics and Child Health. 2025;61(1):7-11. doi:10.1111/jpc.16734

BibTeX
@article{Wright2025,
  author = {Wright, Daniel and Pang, Ken C and Giordano, Simona and Gillam, Lynn},
  title = {Evaluating the benefits and risks of puberty blockers and gender‐affirming hormones for transgender adolescents},
  journal = {Journal of Paediatrics and Child Health},
  year = {2025},
  volume = {61},
  number = {1},
  pages = {7--11},
  doi = {10.1111/jpc.16734}
}
Kostenlos starten →